Global Study of MK-2060 (Anti-Factor XI Monoclonal Antibody) in Participants With End Stage Renal Disease Receiving Hemodialysis (FXI Hemodialysis Study) (MK-2060-007)
A Randomized Parallel-group, Placebo-controlled, Double-blind, Event-driven, Multi-center Phase 2 Clinical Outcome Trial of Prevention of Arteriovenous Graft Thrombosis and Safety of MK-2060 in Patients With End Stage Renal Disease Receiving Hemodialysis
Sponsor: Merck Sharp & Dohme LLC
A PHASE2 clinical study on End-Stage Kidney Disease and End-Stage Renal Disease, this trial is completed. The trial is conducted by Merck Sharp & Dohme LLC and has accumulated 28 data snapshots since 2021. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
28 versions recorded-
Feb 2026 — Present [monthly]
Completed PHASE2
-
Dec 2025 — Feb 2026 [monthly]
Completed PHASE2
-
Sep 2025 — Dec 2025 [monthly]
Completed PHASE2
-
Apr 2025 — Sep 2025 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Jan 2025 — Apr 2025 [monthly]
Active Not Recruiting PHASE2
▶ Show 23 earlier versions
-
Dec 2024 — Jan 2025 [monthly]
Active Not Recruiting PHASE2
-
Sep 2024 — Dec 2024 [monthly]
Active Not Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE2
-
Oct 2023 — Jul 2024 [monthly]
Active Not Recruiting PHASE2
-
Aug 2023 — Oct 2023 [monthly]
Active Not Recruiting PHASE2
-
Apr 2023 — Aug 2023 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Mar 2023 — Apr 2023 [monthly]
Recruiting PHASE2
-
Feb 2023 — Mar 2023 [monthly]
Recruiting PHASE2
-
Jan 2023 — Feb 2023 [monthly]
Recruiting PHASE2
-
Dec 2022 — Jan 2023 [monthly]
Recruiting PHASE2
-
Nov 2022 — Dec 2022 [monthly]
Recruiting PHASE2
-
Sep 2022 — Nov 2022 [monthly]
Recruiting PHASE2
-
Jul 2022 — Sep 2022 [monthly]
Recruiting PHASE2
-
Jun 2022 — Jul 2022 [monthly]
Recruiting PHASE2
-
May 2022 — Jun 2022 [monthly]
Recruiting PHASE2
-
Apr 2022 — May 2022 [monthly]
Recruiting PHASE2
-
Mar 2022 — Apr 2022 [monthly]
Recruiting PHASE2
-
Feb 2022 — Mar 2022 [monthly]
Recruiting PHASE2
-
Jan 2022 — Feb 2022 [monthly]
Recruiting PHASE2
-
Dec 2021 — Jan 2022 [monthly]
Recruiting PHASE2
-
Nov 2021 — Dec 2021 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Oct 2021 — Nov 2021 [monthly]
Not Yet Recruiting PHASE2
-
Sep 2021 — Oct 2021 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Merck Sharp & Dohme LLC
For direct contact, visit the study record on ClinicalTrials.gov .